Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 79.37B +27.4% |
| Revenue (ttm) | 15.53B +9.3% |
| Net Income | 4.33B -2.9% |
| EPS | 40.43 +1.9% |
| Shares Out | 99.85M |
| PE Ratio | 19.98 |
| Forward PE | 13.29 |
| Dividend | $3.76 (0.47%) |
| Ex-Dividend Date | Aug 18, 2026 |
| Volume | 101,472 |
| Open | 809.40 |
| Previous Close | 807.71 |
| Day's Range | 792.68 - 809.40 |
| 52-Week Range | 541.00 - 847.00 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 840.43 (+5.73%) |
| Earnings Date | Jul 30, 2026 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $840.43, which is an increase of 5.73% from the latest price.
News
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who pur...
Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims
A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share price. The plaintiffs in the lawsuit allege…
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
US FDA approves Regeneron's rare bone disorder drug
The U.S. FDA on Wednesday approved Regeneron's experimental drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
Regeneron price target raised to $824 from $641 at Leerink
Leerink analyst David Risinger raised the firm’s price target on Regeneron (REGN) to $824 from $641 and keeps a Market Perform rating on the shares.
Regeneron announces Health Canada approval of new indication for Libtayo
Regeneron (REGN) Canada announced that Health Canada has issued a Notice of Compliance for Libtayo for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma at high risk…
Regeneron price target raised to $1,030 from $1,000 at Guggenheim
Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,030 from $1,000 and keeps a Buy rating on the shares following what the firm calls ” a clean beat…
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg
BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #biosimilar--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg, Used to Treat Various Types of Ophth...
Regeneron price target raised to $740 from $700 at Citi
Citi raised the firm’s price target on Regeneron (REGN) to $740 from $700 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Regeneron price target raised to $737 from $696 at RBC Capital
RBC Capital raised the firm’s price target on Regeneron (REGN) to $737 from $696 and keeps a Sector Perform rating on the shares. The company reported strong sales across the…
Regeneron price target raised to $758 from $730 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $758 from $730 and keeps an Equal Weight rating on the shares after “a solid 2Q beat on both…
Regeneron price target raised to $891 from $856 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Regeneron (REGN) to $891 from $856 and keeps a Buy rating on the shares. Dupixent’s beat in Q2 raises the…
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Regeneron (REGN) to $795 from $750 and keeps an Overweight rating on the shares. Regeneron’s Q2 results reduced near-term…
Regeneron price target raised to $761 from $742 at Baird
Baird raised the firm’s price target on Regeneron (REGN) to $761 from $742 and keeps a Neutral rating on the shares. The firm updated its model following impressive Q2 results…
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 ...
Regeneron price target raised to $750 from $700 at Wells Fargo
Wells Fargo raised the firm’s price target on Regeneron (REGN) to $750 from $700 and keeps an Equal Weight rating on the shares. The firm believes the company’s Q2 reinforces…
Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 17% year-over-year to $4.3B, with double-digit EPS growth and record sales for Dupixent, EYLEA HD, and Libtayo. Pipeline advances and upcoming regulatory milestones support a strong outlook, while robust cash flow enables continued R&D and shareholder returns.
Regeneron Pharmaceuticals Earnings release: Q2 2026
Regeneron Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q2 2026
Regeneron Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Regeneron Pharmaceuticals Slides: Q2 2026
Regeneron Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
08:17 EDT Regeneron (REGN) cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea.
Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20
Reports Q2 revenue $4.3B, consensus $3.83B. “Regeneron (REGN) delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength...
Regeneron Reports Second Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update.